Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.

Cancer
Amgen thinks Five Prime's bemarituzumab offers utility in various tumor types

Amgen, Inc. announced on 4 March that it will pay $1.9bn to acquire Five Prime Therapeutics, Inc. in a deal that someanalysts see as a potential precursor to larger business development by the company. Amgen’s purchase was motivated by the strength of Five Prime’s Phase III-ready, first-in-class FGFR2b-targeting antibody bemarituzumab in the treatment of HER-negative gastric cancer.

The acquisition gives Amgen a much-needed addition to its late-stage research and development pipeline and the company said it sees...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.